|
Effect of ethnicity and chemotherapy (mFOLFOX6) on zolbetuximab pharmacokinetics in patients with claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ). |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - TP Therapeutics |
|
Consulting or Advisory Role - Astellas Pharma; Boston Biomedical; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Foundation Medicine; Lilly; Merck; Pieris Pharmaceuticals |
Speakers' Bureau - Foundation Medicine |
Research Funding - BeiGene (Inst); Leap Therapeutics (Inst) |
Other Relationship - NCCN |
|
|
Employment - Abbvie; Astellas Pharma |
|
|
Employment - Astellas Pharma |
Stock and Other Ownership Interests - Abbvie; Amarin Corporation; Aptevo Therapeutics; Aquestive Therapeutics; Johnson & Johnson; Sunesis Pharmaceuticals; Trillium Therapeutics |
|
|
Employment - Astellas Pharma |
Stock and Other Ownership Interests - Astellas Pharma |
|
|
Employment - Astellas Pharma |
Stock and Other Ownership Interests - Astellas Pharma |
|
|
No Relationships to Disclose |
|
|
Employment - Astellas Pharma |
|
|
Employment - Astellas Pharma |
|
|
Consulting or Advisory Role - Amal Therapeutics; Amgen; Bayer; Sanofi |
Speakers' Bureau - Amgen; Bayer; Roche; Sanofi |
Research Funding - Amgen (Inst); Bayer (Inst); Merck Serono (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Amgen; Merck Serono; Roche |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Green Cross; Hanmi; Merck Serono; MSD Oncology; Novartis; Samyang |
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Curis (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |
|
|
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical |
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda |
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst) |